Highest-materiality recent filing
Mesa Labs Q4 revenue up 2.6% but net loss $4.1M; BPD revenue falls 29.9% on export controls
Q4 revenue $63.7M (+2.6% YoY); net loss $4.1M ($0.75 loss per share) vs prior year loss of $7.1M.
CEO Gary Owens to depart by April 13; remains non-executive through June 22
Owens steps down as President and CEO effective ~April 13, 2026; stays in non-executive role until June 22, 2026.
Mesa Labs appoints Siddhartha Kadia as CEO to succeed Gary Owens effective April 13, 2026
Gary Owens departs as President and CEO effective April 12, 2026; separation not due to any disagreement.
Mesa Labs Q3 revenue up 3.6% to $65.1M; net income surges 317% to $3.63M
Revenue $65.1M, +3.6% YoY; core organic growth 1.2%.
Mesa Labs 2Q26 revenue up 5%, net income down 27.8% on tariffs and China headwinds
Total revenues $60.7M, +5.0% YoY; core organic growth 3.7%.
Mesa Laboratories draws $97M under credit facility to repay convertible notes due August 2025
Drew $97M under existing Credit Agreement to settle $97.5M of 1.375% Convertible Senior Notes maturing August 2025; total outstanding under credit facility now $108M.
Mesa Laboratories Reports First Quarter Fiscal 2026 Results
Total revenues increased 2.4% to $59,543,000 for the quarter ended June 30, 2025.
Mesa Labs Q4 revenue up 5.5% but net loss widens to $7.1M
Total revenues $62.1M, up 5.5% YoY; core organic growth 6.3%.
Mesa Labs Q3 revenue up 17.5% to $62.8M; core organic growth 13.2%
Revenue $62.8M (+17.5% YoY); non-GAAP core organic revenue +13.2%.
Revenue $57.8M (+8.8% YoY); net income $3.4M ($0.63 diluted EPS) vs. prior year loss.
Mesa Labs Q1 revenue $58.2M (+14.9%), EPS $0.62; operating income up 940%
Revenue $58.2M (+14.9% YoY); net income $3.4M (+717%); diluted EPS $0.62.
Mesa Labs Q4 net loss of $254.6M on $274.5M impairment; core organic revenues down 3.5%
Q4 revenue $58.9M (+6% YoY); core organic revenue declined 3.5% due to headwinds in Clinical Genomics and Biopharma.
Amended credit agreement: $75M term loan + $125M revolver, matures April 2029, interest at SOFR + 1.5%-3.5%.
Mesa Labs expects $271M non-cash impairment charge for FY2024, impacting two divisions
Non-cash impairment of ~$271M for Clinical Genomics and Biopharmaceutical Development divisions in Q4 FY2024.
Mesa Labs Q3 revenue down 1.5%; operating loss of $67K; core organic revenue declines 9%
Revenue $53.5M, down 1.5% YoY; core organic revenue declined 9%.
Effective January 5, 2024, the Board of Directors (“Board”) of Mesa Laboratories, Inc. (“Mesa ”), upon the recommendation of its Nominating and Governance Committee, voted to expand the size of the Board from six to seven members, and to appoint Mark Capone to fill the newly created seat.
Max materiality 0.85 · Median 0.70 · Most common event earnings